Real-World Outcomes of Tirzepatide and Semaglutide in 40,000+ Patients
Sustained Real-World Weight Loss in 40,000+ Patients
Substantial weight loss was achieved with GLP-1–based pharmacotherapy within a comprehensive digital obesity care model. Outcomes were maintained up to 24 months, with 57% of patients still in treatment, demonstrating strong long-term effectiveness in real-world care.
The Yazen Model - Modern Obesity Treatment Given Via a Digital Care Model. A Descriptive Analysis
The Yazen Model goes beyond traditional methods, providing patients with the tools to manage their disease, addressing medical and behavioural aspects, education and social support via a digital platform for accessible, continuous and effective weight loss and management.


.webp)
.webp)